Title: | Predictive equation of metastasis in patients with malignant ovarian epithelial tumors with the Ca-125 marker |
Other Titles: | |
Authors: | Sanchez Vega, Juan Fernando Murillo Bacilio, Magdali Del rocio Vintimilla Condoy, Adrian Santiago Palta Gonzalez, Araceli Miroslava Crespo Astudillo, Jose Alfredo Mora Bravo, Franklin Geovany |
Keywords: | Cancer Antigen 125 Ovarian Cancer Prediction Of Metastasis |
metadata.dc.ucuenca.areaconocimientofrascatiamplio: | 3. CIENCIAS MEDICAS Y DE LA SALUD |
metadata.dc.ucuenca.areaconocimientofrascatidetallado: | 3.3.1 CIENCIAS Y SERVICIOS DEL CUIDADO DE LA SALUD |
metadata.dc.ucuenca.areaconocimientofrascatiespecifico: | 3.3 CIENCIAS DE LA SALUD |
metadata.dc.ucuenca.areaconocimientounescoamplio: | 09 - SALUD Y BIENESTAR |
metadata.dc.ucuenca.areaconocimientounescodetallado: | 0912 - MEDICINA |
metadata.dc.ucuenca.areaconocimientounescoespecifico: | 091 - SALUD |
Issue Date: | 2018 |
metadata.dc.ucuenca.volumen: | volumen 18 |
metadata.dc.source: | BMC Cancer |
metadata.dc.identifier.doi: | 10.1186/s12885-018-4499-y |
metadata.dc.type: | ARTÍCULO |
Abstract: | Background: Cancer antigen (CA) 125 (CA-125) is used in ovarian cancer detection and monitoring, whose serum level has a positive correlation with tumor stage. The aim of this study was to obtain a prediction metastasis equation in a group of patients with ovarian cancer based on Ca-125. Methods: A 2-group comparative observational study was conducted at a single oncologic institution (SOLCA) in Cuenca-Ecuador. All patients who were diagnosed with ovarian cancer between January 1996 and December 2016 were included in the current study. Group 1 (G1) patients with the I and II International Federation of Gynecology and Obstetrics (FIGO) stage and Metastasis Group (MG), with III and IV stage, were subdivided. A logistic regression equation was performed to predict metastasis based on Logarithm of serum Ca-125 levels. Results: We included 85 cases in G1 and 64 patients in MG, with 47.8 plusmn; 15 years (G1) and 57.5 ± 13.6 years (MG) of age (P < 0.001). Mortality in G1 was 2 cases (3.1%) and 53 cases (62.4%) in MG (P < 0.001). The CA-125 serum level was 163.5 ± 236 in G1 and 1220.9 ± 1940 u / ml in MG (P < 0.001). The equation to predict metastasis = (Age*0.053) + [(Logarithm Ca-125 value) * 1.078] -8.163 with an OR 2.940 (CI 95% 2.046-4.223) P < 0.001. The sensitivity of the equation was 82.4% and the specificity was 79.7%. Conclusions: It is possible to predict the presence of metastasis in a group of patients with ovarian cancer based on Ca-125. © 2018 The Author(s). |
Description: | Background: Cancer antigen (CA) 125 (CA-125) is used in ovarian cancer detection and monitoring, whose serum level has a positive correlation with tumor stage. The aim of this study was to obtain a prediction metastasis equation in a group of patients with ovarian cancer based on Ca-125. Methods: A 2-group comparative observational study was conducted at a single oncologic institution (SOLCA) in Cuenca-Ecuador. All patients who were diagnosed with ovarian cancer between January 1996 and December 2016 were included in the current study. Group 1 (G1) patients with the I and II International Federation of Gynecology and Obstetrics (FIGO) stage and Metastasis Group (MG), with III and IV stage, were subdivided. A logistic regression equation was performed to predict metastasis based on Logarithm of serum Ca-125 levels. Results: We included 85 cases in G1 and 64 patients in MG, with 47.8 plusmn; 15 years (G1) and 57.5 ± 13.6 years (MG) of age (P < 0.001). Mortality in G1 was 2 cases (3.1%) and 53 cases (62.4%) in MG (P < 0.001). The CA-125 serum level was 163.5 ± 236 in G1 and 1220.9 ± 1940 u / ml in MG (P < 0.001). The equation to predict metastasis = (Age*0.053) + [(Logarithm Ca-125 value) * 1.078] -8.163 with an OR 2.940 (CI 95% 2.046-4.223) P < 0.001. The sensitivity of the equation was 82.4% and the specificity was 79.7%. Conclusions: It is possible to predict the presence of metastasis in a group of patients with ovarian cancer based on Ca-125. © 2018 The Author(s). |
URI: | http://dspace.ucuenca.edu.ec/handle/123456789/31433 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047466509&origin=inward |
metadata.dc.ucuenca.urifuente: | http://www.biomedcentral.com/ |
ISSN: | 1471-2407 |
Appears in Collections: | Artículos
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.